Systemic Steroids and Bronchopulmonary Dysplasia: a Systematic Review and Meta-analysis

Overview

Journal J Perinatol

Specialty Gynecology & Obstetrics

Date 2024 Sep 2

PMID 39223342

Authors

Talkad S Raghuveer

Rosey E Zackula

Richa Lakhotia

Stephanie A Binder

Affiliations

Soon will be listed here.

Abstract

Importance: It is unclear if systemic steroids decrease the risk of Bronchopulmonary Dysplasia (BPD) while increasing the risk of neurodevelopmental impairment (NDI).

Objective: Conduct a systematic review of randomized controlled trials of systemic steroids to evaluate the risk of BPD, mortality, and NDI in premature infants ≤30 weeks.

Data Sources: MEDLINE, EBSCOhost, Web of Science, Cochrane Library, Embase, and CINAHL.

Study Selection: Randomized clinical trials of Dexamethasone (DEX) or Hydrocortisone (HC) to prevent BPD in premature infants ≤ 30 weeks.

Data Extraction And Synthesis: Data were extracted using the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. Random-effects meta-analyses and multivariable meta-regression were conducted.

Main Outcomes And Measures: Primary outcomes were BPD, mortality, and NDI. Secondary outcomes were hypertension, hyperglycemia, sepsis, intestinal perforation, necrotizing enterocolitis (NEC), and retinopathy of prematurity (ROP). The a priori hypothesis was that steroids would reduce the risk of BPD without increasing NDI.

Results: There were 6377 preterm infants in the 44 (32 DEX, 13 HC) selected studies. DEX significantly reduced the risk of BPD, RR = 0.66, (95% CI, 0.56-0.78). The most effective DEX regimen was medium cumulative dose (2 to 3 mg/kg), RR = 0.43 (95% CI, 0.29-0.65); day of initiation <8 days: RR = 0.68, (95% CI, 0.59-0.79); and treatment for ≥14 days: RR = 0.67 (95% CI, 0.55-0.80). HC did not significantly decrease the risk of BPD, RR = 0.98, (95% CI, 0.87-1.10). Neither DEX, (RR = 0.92, 95% CI, 0.78-1.09) nor HC (RR = 0.83, 95% CI, 0.68-1.01) decrease the risk of mortality. The risk of CP was not increased by either DEX (RR = 1.09, 95% CI, 0.55-2.17) or HC (RR = 1.18, 95% CI, 0.75-1.87). There were no significant differences between steroids and placebo for MDI/PDI scores. Multivariable meta-regression models showed that DEX significantly reduced the risk of BPD without increased risk of CP. DEX increased the risk of hypertension and hyperglycemia. Studies showed high heterogeneity, differing treatment regimen, missing data and different rates of follow-up.

Conclusion And Relevance: DEX, but not HC, significantly decreased the risk of BPD. Neither steroid showed an increased risk of NDI or mortality.

Citing Articles

Assessment of systemic steroid use and its determinants among admitted patients at Debre Berhan University Hakim Gizawu Teaching Hospital.

Tsige A, Simegn K, Beyene D, Ayenew K, Wondmkun Y, Endalifer B Sci Rep. 2024; 14(1):30804.

PMID: 39730577 PMC: 11681244. DOI: 10.1038/s41598-024-81425-8.

References

Stoll B, Hansen N, Bell E, Walsh M, Carlo W, Shankaran S . Trends in Care Practices, Morbidity, and Mortality of Extremely Preterm Neonates, 1993-2012. JAMA. 2015; 314(10):1039-51. PMC: 4787615. DOI: 10.1001/jama.2015.10244. View

Bell E, Hintz S, Hansen N, Bann C, Wyckoff M, DeMauro S . Mortality, In-Hospital Morbidity, Care Practices, and 2-Year Outcomes for Extremely Preterm Infants in the US, 2013-2018. JAMA. 2022; 327(3):248-263. PMC: 8767441. DOI: 10.1001/jama.2021.23580. View

Hwang J, Rehan V . Recent Advances in Bronchopulmonary Dysplasia: Pathophysiology, Prevention, and Treatment. Lung. 2018; 196(2):129-138. PMC: 5856637. DOI: 10.1007/s00408-018-0084-z. View

Levy P, Dioneda B, Holland M, Sekarski T, Lee C, Mathur A . Right ventricular function in preterm and term neonates: reference values for right ventricle areas and fractional area of change. J Am Soc Echocardiogr. 2015; 28(5):559-69. PMC: 4532398. DOI: 10.1016/j.echo.2015.01.024. View

Bui C, Pang M, Sehgal A, Theda C, Lao J, Berger P . Pulmonary hypertension associated with bronchopulmonary dysplasia in preterm infants. J Reprod Immunol. 2017; 124:21-29. DOI: 10.1016/j.jri.2017.09.013. View

Donda K, Agyemang C, Adjetey N, Agyekum A, Princewill N, Ayensu M . Tracheostomy trends in preterm infants with bronchopulmonary dysplasia in the United States: 2008-2017. Pediatr Pulmonol. 2021; 56(5):1008-1017. DOI: 10.1002/ppul.25273. View

Collaco J, McGrath-Morrow S . Respiratory Phenotypes for Preterm Infants, Children, and Adults: Bronchopulmonary Dysplasia and More. Ann Am Thorac Soc. 2018; 15(5):530-538. DOI: 10.1513/AnnalsATS.201709-756FR. View

Cheong J, Doyle L . An update on pulmonary and neurodevelopmental outcomes of bronchopulmonary dysplasia. Semin Perinatol. 2018; 42(7):478-484. DOI: 10.1053/j.semperi.2018.09.013. View

Schmidt B, Asztalos E, Roberts R, Robertson C, Sauve R, Whitfield M . Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms. JAMA. 2003; 289(9):1124-9. DOI: 10.1001/jama.289.9.1124. View

10.

Sriram S, Schreiber M, Msall M, Kuban K, Joseph R, O Shea T . Cognitive Development and Quality of Life Associated With BPD in 10-Year-Olds Born Preterm. Pediatrics. 2018; 141(6). PMC: 6317639. DOI: 10.1542/peds.2017-2719. View

11.

Doyle L, Ranganathan S, Mainzer R, Cheong J . Relationships of Severity of Bronchopulmonary Dysplasia with Adverse Neurodevelopmental Outcomes and Poor Respiratory Function at 7-8 Years of Age. J Pediatr. 2024; 269:114005. DOI: 10.1016/j.jpeds.2024.114005. View

12.

Jensen E, Dysart K, Gantz M, McDonald S, Bamat N, Keszler M . The Diagnosis of Bronchopulmonary Dysplasia in Very Preterm Infants. An Evidence-based Approach. Am J Respir Crit Care Med. 2019; 200(6):751-759. PMC: 6775872. DOI: 10.1164/rccm.201812-2348OC. View

13.

Mammel M, Green T, Johnson D, Thompson T . Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia. Lancet. 1983; 1(8338):1356-8. DOI: 10.1016/s0140-6736(83)92139-6. View

14.

Walsh M, Yao Q, Horbar J, Carpenter J, Lee S, Ohlsson A . Changes in the use of postnatal steroids for bronchopulmonary dysplasia in 3 large neonatal networks. Pediatrics. 2006; 118(5):e1328-35. DOI: 10.1542/peds.2006-0359. View

15.

Yoder B, Harrison M, Clark R . Time-related changes in steroid use and bronchopulmonary dysplasia in preterm infants. Pediatrics. 2009; 124(2):673-9. DOI: 10.1542/peds.2008-2793. View

16.

Abiramalatha T, Ramaswamy V, Bandyopadhyay T, Somanath S, Shaik N, Pullattayil A . Interventions to Prevent Bronchopulmonary Dysplasia in Preterm Neonates: An Umbrella Review of Systematic Reviews and Meta-analyses. JAMA Pediatr. 2022; 176(5):502-516. DOI: 10.1001/jamapediatrics.2021.6619. View

17.

Ramaswamy V, Bandyopadhyay T, Nanda D, Bandiya P, Ahmed J, Garg A . Assessment of Postnatal Corticosteroids for the Prevention of Bronchopulmonary Dysplasia in Preterm Neonates: A Systematic Review and Network Meta-analysis. JAMA Pediatr. 2021; 175(6):e206826. PMC: 7961472. DOI: 10.1001/jamapediatrics.2020.6826. View

18.

Doyle L, Davis P, Morley C, McPhee A, Carlin J . Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomized, controlled trial. Pediatrics. 2006; 117(1):75-83. DOI: 10.1542/peds.2004-2843. View

19.

Job S, Clarke P . Current UK practices in steroid treatment of chronic lung disease. Arch Dis Child Fetal Neonatal Ed. 2015; 100(4):F371. DOI: 10.1136/archdischild-2014-308060. View

20.

Cummings J, Pramanik A . Postnatal Corticosteroids to Prevent or Treat Chronic Lung Disease Following Preterm Birth. Pediatrics. 2023; 149(6). DOI: 10.1542/peds.2022-057530. View